Revelation Biosciences shares more than double on allergy treatment data

Revelation Biosciences

25/07/2022 12:04

** Shares of biopharma co  REVB.O  soar ~114% to $1.39
premarket
    ** Co on Friday after market said its experimental
treatment, REVTx-99a, met the main goal of safety and
tolerability versus placebo in an early stage study  urn:newsml:reuters.com:*:nGNX4q13Sg
    ** REVB was testing REVTx-99a, an intranasal formulation, as
a treatment for allergic rhinitis symptoms to rye grass pollen
    ** Allergic rhinitis or hay fever is an allergic response
causing itchy, watery eyes, sneezing and other similar symptoms
    ** Co will continue to develop REVTx-99b for the management
of allergic rhinitis symptoms such as chronic nasal congestion
    ** Stock down ~83.6% YTD, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com;))